Century Therapeutics (IPSC) News Today $0.50 -0.02 (-2.91%) Closing price 08/28/2025 04:00 PM EasternExtended Trading$0.51 +0.01 (+1.98%) As of 09:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IPSC Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Century Therapeutics to Present at Global Investment ConferenceAugust 23, 2025 | msn.comHC Wainwright Analysts Raise Earnings Estimates for IPSCAugust 23, 2025 | americanbankingnews.comCentury Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 22, 2025 | globenewswire.comCentury Therapeutics (NASDAQ:IPSC) Rating Lowered to Sell at Wall Street ZenAugust 18, 2025 | americanbankingnews.comCentury Therapeutics, Inc.: Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 15, 2025 | finanznachrichten.deCentury Reports Flat Loss in Fiscal Q2August 15, 2025 | theglobeandmail.comCentury Therapeutics Reports Q2 2025 Financials and UpdatesAugust 14, 2025 | tipranks.comCentury Therapeutics Reports Q2 Results and Leadership ChangeAugust 14, 2025 | msn.comCentury Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comCentury Therapeutics (NASDAQ:IPSC) Shares Down 8.7% - Here's WhyJuly 30, 2025 | marketbeat.comCentury Therapeutics Inc. Stock Grades | IPSC | Barron'sJuly 16, 2025 | barrons.comUniversity City biotech Century Therapeutics is cutting 72 jobs, about half its workforceJuly 11, 2025 | msn.comCentury Therapeutics to Cut 51% of WorkforceJuly 8, 2025 | marketwatch.comCentury Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum - NasdaqJune 27, 2025 | nasdaq.comCentury Therapeutics, Inc. (IPSC) - Yahoo FinanceJune 26, 2025 | sg.finance.yahoo.comIPSC Century Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comCentury Therapeutics to Present Preclinical Data at EULAR 2025 CongressMay 31, 2025 | msn.comCentury Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 CongressMay 28, 2025 | globenewswire.comQ2 EPS Estimate for Century Therapeutics Lowered by AnalystMay 23, 2025 | marketbeat.comCentury Therapeutics, Inc.: Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | finanznachrichten.deCentury Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comCentury Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual MeetingMay 1, 2025 | msn.comCentury Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual MeetingApril 28, 2025 | globenewswire.comPiper Sandler Remains a Buy on Century Therapeutics (IPSC)April 24, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Intuitive Surgical (ISRG) and Century Therapeutics (IPSC)April 23, 2025 | markets.businessinsider.comCentury Therapeutics Hosts Live Fireside Chat on Groundbreaking Cell Therapy AdvancesApril 17, 2025 | msn.comCentury Therapeutics price target lowered to $5 from $12 at GuggenheimMarch 21, 2025 | markets.businessinsider.comCentury Therapeutics Announces Pipeline Re-Prioritization to Focus on Transformational Programs and Extends Cash Runway into Q4 2026March 21, 2025 | nasdaq.comCentury Therapeutics (IPSC) Receives a Buy from Piper SandlerMarch 21, 2025 | markets.businessinsider.comCentury Therapeutics price target lowered to $2 from $4 at Piper SandlerMarch 21, 2025 | markets.businessinsider.comCentury Therapeutics Announces Strategic Pipeline Shift and 2024 Financial ResultsMarch 21, 2025 | msn.com3IPSC : Demystifying Century Therapeutics: Insights From 4 Analyst ReviewsMarch 21, 2025 | benzinga.comCentury Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | globenewswire.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Average Recommendation of "Buy" by BrokeragesMarch 13, 2025 | marketbeat.comCentury Therapeutics (IPSC) Expected to Announce Quarterly Earnings on ThursdayMarch 6, 2025 | marketbeat.comLeerink Partnrs Has Strong Forecast for IPSC FY2024 EarningsFebruary 17, 2025 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Buy" by AnalystsFebruary 16, 2025 | marketbeat.comFY2029 Earnings Estimate for IPSC Issued By Leerink PartnrsFebruary 15, 2025 | marketbeat.comLeerink Partners Remains a Buy on Century Therapeutics (IPSC)February 14, 2025 | markets.businessinsider.comCentury Therapeutics SVP sells shares worth $273 to cover taxesFebruary 5, 2025 | msn.comCentury Therapeutics COO Farid Adrienne sells $822 in stockFebruary 5, 2025 | msn.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in JanuaryFebruary 1, 2025 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of "Buy" by BrokeragesJanuary 22, 2025 | marketbeat.comGuggenheim Reaffirms "Buy" Rating for Century Therapeutics (NASDAQ:IPSC)January 22, 2025 | marketbeat.comCentury Therapeutics (NASDAQ:IPSC) Receives "Buy" Rating from HC WainwrightJanuary 22, 2025 | marketbeat.comCentury Therapeutics launches cell therapy trial for autoimmune diseasesJanuary 21, 2025 | msn.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Up 14.0% in DecemberJanuary 18, 2025 | marketbeat.comCentury Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Down 5.6% in DecemberJanuary 1, 2025 | marketbeat.comCentury Therapeutics price target lowered to $4 from $12 at Piper SandlerDecember 30, 2024 | markets.businessinsider.comCentury Therapeutics (NASDAQ:IPSC) Given New $4.00 Price Target at Piper SandlerDecember 30, 2024 | marketbeat.com Get Century Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IPSC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPSC Media Mentions By Week IPSC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IPSC News Sentiment▼0.581.03▲Average Medical News Sentiment IPSC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IPSC Articles This Week▼41▲IPSC Articles Average Week Get the Latest News and Ratings for IPSC and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Century Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CCCC News TNYA News TIL News SXTC News DERM News IMRX News NVCT News ACTU News CRBU News TVGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IPSC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Century Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Century Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access